All News
Filter News
Found 808,890 articles
-
Ocugen to Host Conference Call on Friday, May 7 at 8:30 a.m. ET to Discuss First Quarter 2021 Financial Results and Provide Business Update
5/3/2021
Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a conference call to discuss its first quarter 2021 financial results and provide a business update at 8:30 a.m. ET on Friday, May 7, 2021.
-
LogicBio Announces Presentation of Retrospective Study of Disease Course in Pediatric Patients with Severe Methylmalonic Acidemia
5/3/2021
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced results from a retrospective study of the disease course in pediatric patients living with severe methylmalonic acidemia
-
Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021
5/3/2021
Incyte (Nasdaq:INCY) today announced that multiple abstracts from its dermatology portfolio highlighting data on ruxolitinib cream, a selective JAK1/JAK2 inhibitor designed for topical application, in patients with atopic dermatitis (AD) will be presented at the Society for Investigative Dermatology (SID) Virtual Meeting 2021, held virtually from May 3-8, 2021.
-
Sesen Bio to Host Conference Call to Review First Quarter 2021 Financial Results and Provide Business Update on Monday, May 10, 2021
5/3/2021
Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that the Company’s management team will host a conference call to review operating results for the first quarter ended March 31, 2021 and provide a business update. The conference call is scheduled for Monday, May 10, 2021 at 8:00 am ET.
-
bluebird bio Announces May Investor Events
5/3/2021
bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences: BofA Securities 2021 Health Care Conference, Thursday, May 13, at 9:30 am ET 2021 RBC Capital Markets Global Healthcare Conference, Wednesday, May 19, at 1:55 pm ET
-
ATS 2021 Breaking News Session to Feature Pivotal Data on REGEN-COV™ (casirivimab with imdevimab) and Dupixent® (dupilumab)
5/3/2021
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that positive Phase 3 data from trials evaluating two Regeneron medicines will be featured at the 2021 American Thoracic Society International Conference (ATS 2021) in the Breaking News: Clinical Trial Results in Pulmonary Medicine Scientific Symposium on May 17, 2021
-
BioXcel Therapeutics to Host First Quarter 2021 Operating and Financial Results Conference Call and Webcast
5/3/2021
- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced it will host a conference call and webcast on Monday, May 10, 2021 at 8:30 AM Eastern Time to discuss its first quarter 2021 operating and financial results.
-
HOOKIPA Pharma to Report First Quarter 2021 Financial Results on Wednesday, May 12, 2021
5/3/2021
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release first quarter 2021 financial results before the market opens on Wednesday, May 12, 2021.
-
Compugen to Release First Quarter 2021 Results on Thursday, May 13, 2021
5/3/2021
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its first quarter 2021 financial results on Thursday, May 13, 2021 before the U.S. financial markets open.
-
Cocrystal Pharma Provides Update on its COVID-19 Antiviral Discovery and Development Programs
5/3/2021
Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coronaviruses, hepatitis C viruses and noroviruses, announces progress in developing broad-spectrum antiviral drug candidates that target coronaviruses including SARS-CoV-2, the coronavirus that causes COVID-19.
-
Alkermes to Showcase Data From Psychiatry Portfolio at Upcoming Scientific Conferences Throughout Mental Health Awareness Month
5/3/2021
Alkermes plc (Nasdaq: ALKS) today announced plans to present clinical data and outcomes research from its psychiatry portfolio at three scientific conferences during Mental Health Awareness Month in May.
-
Homology Medicines Presents Data Demonstrating In Vivo Transduction of Non-Human Primate and Human Retinal Cells at ARVO Annual Meeting
5/3/2021
Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today new preclinical data that demonstrated in vivo nuclease-free gene editing of retinal cells at the virtual Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.
-
Miravo Healthcare Announces First Quarter 2021 Results Release Date and Virtual Annual Meeting of Shareholders
5/3/2021
Nuvo Pharmaceuticals Inc. (TSX: MRV) (OTCQX: MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced it expects to release its first quarter 2021 financial results before markets open on Monday, May 17, 2021 .
-
AVEO Oncology to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 10, 2021
5/3/2021
AVEO Oncology to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 10, 2021
-
Aura Biosciences Presents New Preclinical AU-011 Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
5/3/2021
AU-011 Demonstrates Targeted Cytotoxicity In Vitro and In Vivo in Both Breast and Lung Tumors, Demonstrating the Potential to Treat Human Choroidal Metastases Tumor Distribution of AU-011 in the Treatment of Choroidal Melanoma Also Presented Using Intravitreal and Suprachoroidal Administration
-
Mersana Therapeutics to Host Conference Call Announcing First Quarter 2021 Financial Results and Business Updates
5/3/2021
Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will host a conference call and webcast on Monday, May 10, 2021 at 4:30 p.m. ET
-
Precision BioSciences Announces Paper Presentation at the Association for Research in Vision and Ophthalmology 2021 Annual Meeting
5/3/2021
Precision BioSciences Announces Paper Presentation at the Association for Research in Vision and Ophthalmology 2021 Annual Meeting Preclinical Research with ARCUS Genome Editing Rejuvenated Rod Photoreceptor Structure and Function in a Transgenic Pig Model of Human Blindness
-
Darling Ingredients' Rousselot® Brand Reinforces its Application Sciences Leadership with a Renewed State-of-the-Art Application Lab in Brazil
5/3/2021
Darling Ingredients' (NYSE: DAR) Rousselot® brand and the global leader of collagen-based solutions1, announces the reopening of its upgraded Brazilian innovation lab.
-
BioSig Technologies, Inc. Invited to Present at Wall Street Conference
5/3/2021
BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that Ken Londoner, Chairman and CEO of BioSig Technologies, Inc. will provide a keynote update during the Wall Street Conference on Wednesday, May 5, 2021, at 12:05 pm ET.
-
Ichnos Sciences Presents Positive Data From Ongoing Phase 2b Study Of Telazorlimab In Atopic Dermatitis At The 2021 SID Virtual Meeting
5/3/2021
Ichnos Sciences Inc., a global biotechnology company developing innovative biologic treatments in oncology and autoimmune diseases, today presented positive data from a Phase 2b study of telazorlimab in atopic dermatitis